Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 16/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 13/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.46 |
| ▸ | PI4KA | P42356 | 3/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22326710 | 0.80 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL18520820 | 0.79 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL18526490 | 0.74 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL24222092 | 0.72 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL18520815 | 0.72 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL22326770 | 0.70 | ADORA2A (0.47) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL22571151 | 0.70 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL22571152 | 0.68 | PI4KA (0.50) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL18510391 | 0.68 | ADORA2A (0.67) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL22381523 | 0.67 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BADORA3PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | ADORA2A 72/4885ADORA1 36/4885ADORA2B 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.